ADMA Biologics, Inc. (ADMA)
Automate Your Wheel Strategy on ADMA
With Tiblio's Option Bot, you can configure your own wheel strategy including ADMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADMA
- Rev/Share 2.0476
- Book/Share 1.8071
- PB 9.6949
- Debt/Equity 0.1928
- CurrentRatio 7.1279
- ROIC 0.3238
- MktCap 4169720843.0
- FreeCF/Share 0.1707
- PFCF 102.3873
- PE 19.9589
- Debt/Assets 0.1462
- DivYield 0
- ROE 0.5398
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $17.5, denoting a +1.16% move from the preceding trading day.
Read More
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.
Read More
ADMA Biologics: Business Update And My Price Target
Published: January 14, 2026 by: Seeking Alpha
Sentiment: Neutral
ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider buying, and a poison pill signaled management's confidence in profitability.
Read More
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
Read More
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Adma Biologics (ADMA) and Artivion (AORT) have performed compared to their sector so far this year.
Read More
Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
Read More
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Negative
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 60.24%: Read This Before Placing a Bet
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 60.2% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Adma Biologics (ADMA) Upgraded to Buy: Here's What You Should Know
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Adma Biologics (ADMA) and Cronos Group (CRON) have performed compared to their sector so far this year.
Read More
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Read More
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Read More
Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ADMA broke through the 50-day moving average, which suggests a short-term bullish trend.
Read More
Wall Street Analysts Believe Adma Biologics (ADMA) Could Rally 108.5%: Here's is How to Trade
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 108.5% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
Read More
ADMA Biologics Inc (ADMA) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
RAMSEY, N.J. and BOCA RATON, Fla.
Read More
3 Biotech Stocks I Am Accumulating
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Positive
The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call trade candidates due to the liquidity and lucrativeness of the option premiums against these equities. Stocks had their biggest decline last Friday since the first half of April due to escalating trade tensions between the U.S. and China.
Read More
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
Read More
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
RAMSEY, N.J. and BOCA RATON, Fla.
Read More
Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
The latest trading day saw Adma Biologics (ADMA) settling at $18.26, representing a +1.44% change from its previous close.
Read More
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Will Strong Asceniv Sales Drive ADMA Biologics Further?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
Read More
About ADMA Biologics, Inc. (ADMA)
- IPO Date 2013-10-17
- Website https://www.admabiologics.com
- Industry Biotechnology
- CEO Adam S. Grossman
- Employees 685